Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung 2022-06, Vol.200 (3), p.283-299
Hauptverfasser: Teerapuncharoen, Krittika, Bag, Remzi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 299
container_issue 3
container_start_page 283
container_title Lung
container_volume 200
creator Teerapuncharoen, Krittika
Bag, Remzi
description Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.
doi_str_mv 10.1007/s00408-022-00539-w
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2672323337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A707515283</galeid><sourcerecordid>A707515283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</originalsourceid><addsrcrecordid>eNp9kV1LHDEYhUOx1NX2D_RCBKF4E_smmXzspSytCkJ7sfdhMvPO7kgmWZMZxH9vtmv9KEsJ4SXJcw7hHEK-MrhgAPp7BqjAUOCcAkgxpw8fyIxVglOmJRyQGYiKUV6gQ3KU8x0A04rJT-RQSFUJA3xG6GKdYuib02WZg4tYti_H35MfYqjT4-n14wbTiCH3MXwmH7vaZ_zyPI_J8ueP5eKa3v66ullc3tJGgh4pcxW6DmEu0SjX6lYCcq5M67oKWmjnkjllQFXGKKUMa5lylZSGK46mceKYnO9sNyneT5hHO_S5Qe_rgHHKlivNBRdC6IKe_YPexSmF8rktZUALweev1Kr2aPvQxTHVzdbUXmrQkkluRKHoHmqFAVPtY8CuL9fv-Is9fFktDn2zV_DtjWCNtR_XOfppLNHm9yDfgU2KOSfs7Cb1Q2nDMrDb7u2ue1u6t3-6tw9FdPIcxeQGbF8kf8sugNgBuTyFFabXrP5j-wTNybUj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2678073329</pqid></control><display><type>article</type><title>Chronic Thromboembolic Pulmonary Hypertension</title><source>SpringerLink Journals</source><creator>Teerapuncharoen, Krittika ; Bag, Remzi</creator><creatorcontrib>Teerapuncharoen, Krittika ; Bag, Remzi</creatorcontrib><description>Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.</description><identifier>ISSN: 0341-2040</identifier><identifier>EISSN: 1432-1750</identifier><identifier>DOI: 10.1007/s00408-022-00539-w</identifier><identifier>PMID: 35643802</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Angiography ; Angioplasty ; Anticoagulants ; Balloon treatment ; Care and treatment ; Computed tomography ; CT imaging ; Diagnosis ; Dyspnea ; Embolism ; Health aspects ; Hypertension ; Intolerance ; Medicine ; Medicine &amp; Public Health ; Occlusion ; Patients ; Perfusion ; Pneumology/Respiratory System ; Pulmonary arteries ; Pulmonary artery ; Pulmonary embolism ; Pulmonary embolisms ; Pulmonary hypertension ; Respiration ; State of the Art Review ; Thromboembolism</subject><ispartof>Lung, 2022-06, Vol.200 (3), p.283-299</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</citedby><cites>FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</cites><orcidid>0000-0003-4804-3088 ; 0000-0001-8313-6015</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00408-022-00539-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00408-022-00539-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35643802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teerapuncharoen, Krittika</creatorcontrib><creatorcontrib>Bag, Remzi</creatorcontrib><title>Chronic Thromboembolic Pulmonary Hypertension</title><title>Lung</title><addtitle>Lung</addtitle><addtitle>Lung</addtitle><description>Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.</description><subject>Angiography</subject><subject>Angioplasty</subject><subject>Anticoagulants</subject><subject>Balloon treatment</subject><subject>Care and treatment</subject><subject>Computed tomography</subject><subject>CT imaging</subject><subject>Diagnosis</subject><subject>Dyspnea</subject><subject>Embolism</subject><subject>Health aspects</subject><subject>Hypertension</subject><subject>Intolerance</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Occlusion</subject><subject>Patients</subject><subject>Perfusion</subject><subject>Pneumology/Respiratory System</subject><subject>Pulmonary arteries</subject><subject>Pulmonary artery</subject><subject>Pulmonary embolism</subject><subject>Pulmonary embolisms</subject><subject>Pulmonary hypertension</subject><subject>Respiration</subject><subject>State of the Art Review</subject><subject>Thromboembolism</subject><issn>0341-2040</issn><issn>1432-1750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kV1LHDEYhUOx1NX2D_RCBKF4E_smmXzspSytCkJ7sfdhMvPO7kgmWZMZxH9vtmv9KEsJ4SXJcw7hHEK-MrhgAPp7BqjAUOCcAkgxpw8fyIxVglOmJRyQGYiKUV6gQ3KU8x0A04rJT-RQSFUJA3xG6GKdYuib02WZg4tYti_H35MfYqjT4-n14wbTiCH3MXwmH7vaZ_zyPI_J8ueP5eKa3v66ullc3tJGgh4pcxW6DmEu0SjX6lYCcq5M67oKWmjnkjllQFXGKKUMa5lylZSGK46mceKYnO9sNyneT5hHO_S5Qe_rgHHKlivNBRdC6IKe_YPexSmF8rktZUALweev1Kr2aPvQxTHVzdbUXmrQkkluRKHoHmqFAVPtY8CuL9fv-Is9fFktDn2zV_DtjWCNtR_XOfppLNHm9yDfgU2KOSfs7Cb1Q2nDMrDb7u2ue1u6t3-6tw9FdPIcxeQGbF8kf8sugNgBuTyFFabXrP5j-wTNybUj</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Teerapuncharoen, Krittika</creator><creator>Bag, Remzi</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4804-3088</orcidid><orcidid>https://orcid.org/0000-0001-8313-6015</orcidid></search><sort><creationdate>20220601</creationdate><title>Chronic Thromboembolic Pulmonary Hypertension</title><author>Teerapuncharoen, Krittika ; Bag, Remzi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiography</topic><topic>Angioplasty</topic><topic>Anticoagulants</topic><topic>Balloon treatment</topic><topic>Care and treatment</topic><topic>Computed tomography</topic><topic>CT imaging</topic><topic>Diagnosis</topic><topic>Dyspnea</topic><topic>Embolism</topic><topic>Health aspects</topic><topic>Hypertension</topic><topic>Intolerance</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Occlusion</topic><topic>Patients</topic><topic>Perfusion</topic><topic>Pneumology/Respiratory System</topic><topic>Pulmonary arteries</topic><topic>Pulmonary artery</topic><topic>Pulmonary embolism</topic><topic>Pulmonary embolisms</topic><topic>Pulmonary hypertension</topic><topic>Respiration</topic><topic>State of the Art Review</topic><topic>Thromboembolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teerapuncharoen, Krittika</creatorcontrib><creatorcontrib>Bag, Remzi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Lung</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teerapuncharoen, Krittika</au><au>Bag, Remzi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic Thromboembolic Pulmonary Hypertension</atitle><jtitle>Lung</jtitle><stitle>Lung</stitle><addtitle>Lung</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>200</volume><issue>3</issue><spage>283</spage><epage>299</epage><pages>283-299</pages><issn>0341-2040</issn><eissn>1432-1750</eissn><abstract>Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35643802</pmid><doi>10.1007/s00408-022-00539-w</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-4804-3088</orcidid><orcidid>https://orcid.org/0000-0001-8313-6015</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0341-2040
ispartof Lung, 2022-06, Vol.200 (3), p.283-299
issn 0341-2040
1432-1750
language eng
recordid cdi_proquest_miscellaneous_2672323337
source SpringerLink Journals
subjects Angiography
Angioplasty
Anticoagulants
Balloon treatment
Care and treatment
Computed tomography
CT imaging
Diagnosis
Dyspnea
Embolism
Health aspects
Hypertension
Intolerance
Medicine
Medicine & Public Health
Occlusion
Patients
Perfusion
Pneumology/Respiratory System
Pulmonary arteries
Pulmonary artery
Pulmonary embolism
Pulmonary embolisms
Pulmonary hypertension
Respiration
State of the Art Review
Thromboembolism
title Chronic Thromboembolic Pulmonary Hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T13%3A18%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20Thromboembolic%20Pulmonary%20Hypertension&rft.jtitle=Lung&rft.au=Teerapuncharoen,%20Krittika&rft.date=2022-06-01&rft.volume=200&rft.issue=3&rft.spage=283&rft.epage=299&rft.pages=283-299&rft.issn=0341-2040&rft.eissn=1432-1750&rft_id=info:doi/10.1007/s00408-022-00539-w&rft_dat=%3Cgale_proqu%3EA707515283%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2678073329&rft_id=info:pmid/35643802&rft_galeid=A707515283&rfr_iscdi=true